Compare Amgen, Inc. (AMGN) vs Docusign Inc (DOCU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Docusign Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Docusign Inc trades at $49.66 (market cap $9.39B). The key difference: Amgen, Inc. is far larger — about 20.9× Docusign Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Docusign Inc pays none. Which is the better fit depends on your goals.
| AMGN | DOCU | |
|---|---|---|
Market Cap | $196.12B | $9.39B |
Sector | Health | Technology |
52-Week High | $388.16 | $85.01 |
52-Week Low | $271.18 | $41.75 |
Enterprise Value | $241.41B | $8.76B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
DOCU trades at $49.18, up 0.86% today, with a bullish technical signal from moving averages and strong support near $47. The company reported Q1 2026 EPS of $1.09, beating estimates, and maintains robust gross margins of 79.4%. Recent partnerships with Perplexity and Slack highlight growth in intelligent agreement management, while revenue guidance for 2026 stands at $3.3 billion.
Outlook remains positive with a consensus price target of $55.40, though high valuation multiples (P/E 31.94) and overbought RSI levels pose near-term risks. Competitive pressures in SaaS and reliance on subscription growth are key watchpoints for investors seeking exposure to DOCU's profitable expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
